DMS Pharmaceutical Group Inc.,** Parkridge, Illinois, has been awarded an estimated $197,389,402 modification (P00021) extending the third two-year six-month option period of a two-year six-month base contract (SPE2DX-15-D-9000) with three two-year six-month option periods for prime vendor pharmaceutical and pharmaceutical-related products and support. This is a firm-fixed-price, requirements contract. Locations of performance are inside and outside the continental U.S., with a Nov. 12, 2025, performance completion date. Type of appropriation is fiscal 2025 through 2026 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania. (Awarded Oct. 8, 2024)